Synthesis and anticancer activities of novel 3,5-disubstituted-1,2,4-oxadiazoles.

[1]  S. Shaw.  The structure activity relationship of discodermolide analogues. , 2008, Mini reviews in medicinal chemistry.

[2]  L. Qiu,et al.  Discovery and structure-activity relationship of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers and potential anticancer agents. , 2005, Journal of medicinal chemistry.

[3]  L. Terenius,et al.  Design, synthesis, and evaluation of Phe-Gly mimetics: heterocyclic building blocks for pseudopeptides. , 1999, Journal of medicinal chemistry.

[4]  R S Bohacek,et al.  Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70. , 1999, Journal of medicinal chemistry.

[5]  D. Hadjipavlou-Litina,et al.  Synthesis and biological evaluation of several coumarin-4-carboxamidoxime and 3-(coumarin-4-yl)-1,2,4-oxadiazole derivatives , 1998 .

[6]  J. C. Barnes,et al.  Novel 1, 2, 4-oxadiazoles as potent and selective histamine H3 receptor antagonists , 1996 .

[7]  A. Chimirri,et al.  Synthesis and antitumor activity evaluation of Delta2-1,2,4-oxadiazoline derivatives. , 1996, Farmaco.

[8]  U. Hacksell,et al.  Synthesis of 1,2,4-Oxadiazole-, 1,3,4-Oxadiazole-, and 1,2,4-Triazole-Derived Dipeptidomimetics , 1995 .

[9]  F E Blaney,et al.  Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. , 1991, Journal of medicinal chemistry.

[10]  J. Matsumoto,et al.  A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor. , 1994, Japanese journal of pharmacology.